GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Asset Turnover

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Asset Turnover : 0.00 (As of Dec. 2022)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. CERo Therapeutics Holdings's Revenue for the six months ended in Dec. 2022 was $0.00 Mil. CERo Therapeutics Holdings's Total Assets for the quarter that ended in Dec. 2022 was $17.76 Mil. Therefore, CERo Therapeutics Holdings's Asset Turnover for the quarter that ended in Dec. 2022 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. CERo Therapeutics Holdings's annualized ROE % for the quarter that ended in Dec. 2022 was 81.16%. It is also linked to ROA % through Du Pont Formula. CERo Therapeutics Holdings's annualized ROA % for the quarter that ended in Dec. 2022 was -133.19%.


CERo Therapeutics Holdings Asset Turnover Historical Data

The historical data trend for CERo Therapeutics Holdings's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Asset Turnover Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
Asset Turnover
- -

CERo Therapeutics Holdings Semi-Annual Data
Dec21 Dec22
Asset Turnover - -

Competitive Comparison of CERo Therapeutics Holdings's Asset Turnover

For the Biotechnology subindustry, CERo Therapeutics Holdings's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CERo Therapeutics Holdings's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's Asset Turnover distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's Asset Turnover falls into.



CERo Therapeutics Holdings Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

CERo Therapeutics Holdings's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=0/( (24.176+11.349)/ 2 )
=0/17.7625
=0.00

CERo Therapeutics Holdings's Asset Turnover for the quarter that ended in Dec. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2022 )/( (Total Assets (Q: Dec. 2021 )+Total Assets (Q: Dec. 2022 ))/ count )
=0/( (24.176+11.349)/ 2 )
=0/17.7625
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


CERo Therapeutics Holdings  (NAS:CERO) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

CERo Therapeutics Holdings's annulized ROE % for the quarter that ended in Dec. 2022 is

ROE %**(Q: Dec. 2022 )
=Net Income/Total Stockholders Equity
=-23.658/-29.1495
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-23.658 / 0)*(0 / 17.7625)*(17.7625/ -29.1495)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-0.6094
=ROA %*Equity Multiplier
=-133.19 %*-0.6094
=81.16 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2022) net income data. The Revenue data used here is two times the semi-annual (Dec. 2022) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

CERo Therapeutics Holdings's annulized ROA % for the quarter that ended in Dec. 2022 is

ROA %(Q: Dec. 2022 )
=Net Income/Total Assets
=-23.658/17.7625
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-23.658 / 0)*(0 / 17.7625)
=Net Margin %*Asset Turnover
= %*0
=-133.19 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2022) net income data. The Revenue data used here is two times the semi-annual (Dec. 2022) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


CERo Therapeutics Holdings Asset Turnover Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines